FDA extends Xoft clearance to endometrial cancer treatment
Xoft has received clearance from the FDA for applicators to be used with the Axxent electronic brachytherapy system for the treatment of endometrial cancer. 

Previously cleared for the accelerated treatment of early stage breast cancer, the Axxent System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, also recently received expanded FDA clearance for use in the treatment of other cancers or conditions where radiation therapy is indicated, according to Xoft.

As a platform technology, the Sunnyvale, Calif.-based Xoft said its Axxent electronic brachytherapy system is designed to address a variety of oncological and non-oncological indications. Delivering electronic, x-ray-based radiation treatment, the Axxent treatment platform can be used in clinical settings supervised by a radiation oncologist, according to the company.  

Endometrial cancer, the most prevalent gynecologic cancer in the United States, is also the fourth most common invasive cancer and represents six percent of all cancer in women. According to the National Cancer Institute, more than 40,000 cases will be diagnosed in 2008 and will result in nearly 7,500 deaths.